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Edited by Ivan SadowskiAbstract We have analysed the molecular and cellular regula-
tion of the basic-leucine zipper (bZIP) transcription factor
Nrf3 (NFE2-Related Factor 3). Cycloheximide studies revealed
a rapid turnover of Nrf3. We showed that the proteasome inhib-
itor MG-132 increases Nrf3 protein levels. Furthermore, we
demonstrated that Nrf3 is an N-glycosylated protein associated
with the endoplasmic reticulum. Thus, our studies provide the
ﬁrst evidence of a post-translational modiﬁcation of Nrf3.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The cap ‘n’ collar (CNC) transcription factor family includes
p45-NFE2 [1], Nrf1 (NFE2-related factor 1) [2], Nrf2 [3] and
Nrf3 [4] as well as the more distantly related factors Bach1
(BTB and CNC homology 1) and Bach2 [5]. The CNC factors
heterodimerize with the Maf proto-oncogene factors and the
resulting complexes recognize MARE (Maf recognition ele-
ment) type DNA binding sites [6]. Various studies have dem-
onstrated that Nrf1 and Nrf2 play important roles in
protecting cells against oxidative stress [7–9]. In vitro studiesAbbreviations: ARE, antioxidant response element; ATF6, activating
transcription factor 6; Bach, BTB and CNC homology; Bap31, B-cell
receptor-associated protein 31; bZIP, basic-leucine zipper; CNC, cap
‘n’ collar; ER, endoplasmic reticulum; CREB3L2, cAMP responsive
element binding protein 3-like 2; CREB4, cAMP response element-
binding 4; CREBH, cAMP response element-binding protein H; Endo
H, endoglycosidase H; LDH-A, lactate dehydrogenase A; MARE,
Maf recognition element; NHB1, N-terminal homology box 1; Nrf,
NFE2-related factor; OASIS, old astrocyte speciﬁcally induced sub-
stance; PNGase, peptide-N-glycosidase F; S1P, site-1 protease; S2P,
site-2 protease; SREBP-1, sterol regulatory element binding protein-1;
TBP, TATA box binding protein; Tisp40/AIbZIP, transcript induced
in spermiogenesis 40/androgen-induced bZIP
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doi:10.1016/j.febslet.2007.10.041have shown that Nrf3 may function as a repressor of the anti-
oxidant response element (ARE)-mediated gene expression
[10] but its precise role remains to be elucidated. We have iden-
tiﬁed Nrf3 as a dimerization partner of the small Maf factors
MafF, MafG and MafK [11,12]. We have generated Nrf3 deﬁ-
cient mice that do not display an obvious phenotype under
non-challenging conditions [13]. In the present study, we
showed that Nrf3 displays a short half-life and is rapidly de-
graded in human choriocarcinoma JAR cells. Importantly,
we identiﬁed Nrf3 as a novel endoplasmic reticulum-associated
protein that is Asn-glycosylated.2. Materials and methods
2.1. Reagents and antibodies
The polyclonal antiserum speciﬁc for human Nrf3 was described
elsewhere [11]. Monoclonal antibody against b-Actin is from Sigma–
Aldrich, Inc. (Saint Louis, MI). Rabbit anti-calnexin polyclonal anti-
body was purchased from Stressgen bioreagents Corp. (Victoria,
BC). LDH-A (lactate dehydrogenase A), lamin B and TBP (TATA
box binding protein) polyclonal antibodies are from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA). ImmunoPure goat anti-mouse,
goat anti-rabbit and rabbit anti-goat IgG, (H+L) peroxidase conju-
gated are from Pierce Biotechnology, Inc. (Rockford, IL). Cyclohexi-
mide, thapsigargin and tunicamycin were obtained from Sigma–
Aldrich. MG-132, clasto-lactacystin b-lactone and epoxomicin were
purchased from Calbiochem (San Diego, CA). Tissue culture media
and fetal bovine serum were purchased from HyClone (Logan, UT).
2.2. Cell culture and treatments
Human embryonic kidney 293T (HEK293T) cells were cultured in
high glucose DMEM at 37 C. Human choriocarcinoma JAR cells
were maintained in RPMI-1640 containing 1 mM sodium pyruvate
and 10 mM HEPES. All media contained L-glutamine and were sup-
plemented with 10% fetal bovine serum and 50 U/ml penicillin and
50 lg/ml streptomycin. For treatment studies, the cells were serum-
starved overnight and then incubated with indicated reagents.
2.3. Plasmid constructions and transfection
The pMT2-hNrf3 plasmid encoding full length human Nrf3 has
been described previously [11]. Transient transfection of HEK293T
cells were performed with the calcium phosphate coprecipitation pro-
cedure [14] using 30 lg of expression vectors in a 100-mm dish of
30–50% conﬂuent HEK293T cells.
2.4. Immunoblot analysis
Whole cell extract preparation and separation of proteins on poly-
acrylamide gels have been previously described [11]. To prepare nucle-
ar and cytoplasmic extracts, cell pellets were gently resuspended in an
isotonic lysis buﬀer (10 mM Tris–HCl, pH 7.5; 0.6% NP-40; 2 mM
MgCl2; 3 mM CaCl2 and 0.3 M sucrose) supplemented with protease
inhibitors, incubated on ice for 20 min, layered on a 1.8 M sucroseblished by Elsevier B.V. All rights reserved.
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layer was recovered as cytoplasmic fraction, the nuclear pellet was
washed with isotonic lysis buﬀer without NP-40 and then resuspended
in 30 ll of a cold nuclear buﬀer C (20 mM HEPES pH 7.9; 25% glyc-
erol; 420 mM NaCl; 1.5 mM MgCl2; 0.2 mM EDTA and protease
inhibitors) and incubated for 30 min on ice. Nuclear extract was ob-
tained after a 5 min centrifugation at 10000 · g.
2.5. Glycosylation studies
Treatment with peptide-N-glycosidase F (PNGase) or endoglycosi-
dase H (Endo H) (New England Biolabs Inc, Beverly, MA) was
according to the manufacturer’s instructions. The digested proteins
were analyzed by immunoblotting.
2.6. Isolation of ER-enriched fractions
Endoplasmic reticulum (ER)-enriched fractions were prepared as
described by Wang et al. [15].3. Results and discussion
3.1. Human Nrf3 displays a high turnover
We have previously shown that human Nrf3 is highly ex-
pressed in JAR choriocarcinoma cells [11]. We treated JARFig. 1. Inhibition of protein synthesis by cycloheximide blocks the basal expr
JAR choriocarcinoma cells treated with cycloheximide (5 lg/ml) for 5–120 mi
for the full-length hNrf3 (694 amino acids) or with a control vector without
were subjected to immunoblot analysis with puriﬁed Nrf3-speciﬁc antiserum
probed for actin as loading control. (B) The proteasome inhibitor MG-132 in
for 1, 2, 4 and 6 h or untreated (H2O and DMSO). Whole cell extracts (30
antiserum. Membrane was also probed for actin as loading control. (C) Diﬀer
treated or not with 1 lM MG-132, 500 nM epoxomicin or 5 lM clasto-lac
analyzed by immunoblot with puriﬁed Nrf3-speciﬁc antiserum. Membrane wcells with cycloheximide, a protein synthesis inhibitor, to deter-
mine the rate of Nrf3 turnover. As seen in Fig. 1A, three dif-
ferent bands of human Nrf3 (indicated by arrows) are
observed by immunoblot: a slow migrating form (referred to
as the ‘‘A’’ form), an intermediate ‘‘B’’ form and a faster
migrating ‘‘C’’ form. These three bands are also observed in
HEK293T cells transiently transfected with an expressing vec-
tor coding for full length hNrf3 (Fig. 1A). The same pattern is
obtained by the use of two diﬀerent Nrf3 antisera demonstrat-
ing the authenticity of these three bands (data not shown). A 2-
h cycloheximide treatment of JAR cells resulted in the decrease
of the three diﬀerent Nrf3 forms indicating a short half-life of
endogenous Nrf3 in JAR cells under homeostatic conditions.
Precisely, the ‘‘B’’ form has the highest turnover with an esti-
mated half-life of approximately 15 min, the ‘‘A’’ form has a
half-life of about 20 min whereas the ‘‘C’’ form represents a
more stable form with a half-life of approximately 40 min. In
accordance with this rapid turnover, we found, using the
PESTﬁnd algorithm, a putative PEST motif in the Nrf3 se-
quence which is conserved in diﬀerent species (Fig. 3). It has
been suggested that this sequence, rich in proline (P), glutamic
acid (E), serine (S) and threonine (T) serves as a signal for ra-ession of Nrf3. (A) Immunoblot analysis of total protein extracted from
n. HEK293T cells were transfected with an expression construct coding
insert (pMT2). HEK293T (2 lg) and JAR (30 lg) whole-cell extracts
. Arrows indicate the 3 distinct forms of hNrf3. Membrane was also
creases hNrf3 protein levels. JAR cells were treated with 1 lMMG-132
lg) (WCE) were analyzed by immunoblot with puriﬁed Nrf3-speciﬁc
ent proteasome inhibitors increase hNrf3 protein levels. JAR cells were
tacystin b-lactone for 24 h. Whole cell extracts (30 lg) (WCE) were
as also probed for actin as loading control.
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unclear [16].
To further examine the degradation pathway of Nrf3, we
treated JAR cells with MG-132, a 26S proteasome inhibitor.
We found increased levels of Nrf3 forms as early as 1 h follow-
ing MG-132 treatment and a further augmentation after 2, 4
and 6 h of treatment. To conﬁrm that Nrf3 degradation is pro-
teasome-dependent, JAR cells were treated with two highly
speciﬁc proteasome inhibitors, clasto-lactacystin b-lactone
and epoxomicin (Fig. 1C). Upon these treatments, we observed
accumulation of the ‘‘B’’ and ‘‘C’’ forms of Nrf3 suggesting
that this transcription factor is degraded through the ubiqui-
tin-proteasome pathway. Earlier studies have demonstratedFig. 2. The slower migrating form of hNrf3 is located in the
endoplasmic reticulum. (A) Whole cell extract (WCE), cytoplasmic
(cyt) and nuclei (nuc) fractions were analyzed by immunoblot with
puriﬁed Nrf3-speciﬁc antiserum. LDH-A was used as a cytoplasmic
marker and TBP as a nuclear marker. (B) Aliquots of whole cell
extract (WCE), ER-enriched fractions (ER) and cytosolic fractions
(cytosol) were analyzed by immunoblot with puriﬁed Nrf3-speciﬁc
antiserum. Calnexin was used as an ER membrane marker, lamin B as
a nuclear marker, LDH-A as a cytoplasmic marker and actin as a
loading control.that Nrf2 also exhibits a short half-life and is rapidly degraded
by the ubiquitin-proteasome pathway [17,18]. Taken together,
the results suggest that Nrf3, as Nrf2, is stringently regulated
keeping its levels limited in the cell under normal conditions.3.2. Localization of human Nrf3 in the endoplasmic reticulum
To further characterize the diﬀerent forms of Nrf3, nuclear
and cytoplasmic fractions were prepared. Fig. 2A revealed that
the ‘‘A’’ form of Nrf3 is predominantly found in the cytoplasm
of JAR cells while the ‘‘C’’ form is mostly nuclear. The ‘‘B’’
form of Nrf3, barely detectable in untreated cells, is present
in both compartments when cells are treated with MG-132.
To determine the subcellular localization of Nrf3, ER-enriched
and cytosolic fractions were prepared from JAR cells (Fig. 2B).
Our results show that the ‘‘A’’ form of Nrf3 is mainly located
in the ER-enriched fraction. As evidenced by the presence of
lamin B, the ER-fraction is contaminated by nuclei. However,
we can establish that the ‘‘A’’ form is in the endoplasmic retic-
ulum since we show that this form is present neither in the nu-
clei (Fig. 2A) nor in the cytosol (Fig. 2B). Recently, Nrf1, the
CNC family member most closely related to Nrf3 [11], has
been described to be targeted to the endoplasmic reticulum
through its N-terminal domain [19] and anchored to the ER
through its N-terminal homology box 1 (NHB1) domain
[20]. In accordance with our data, a similar sequence is found
in the N-terminal domain of Nrf3 (Fig. 3 and [20]). Moreover,
MG-132 treatment led to an increase of the ‘‘A’’ form in the
total lysate and ER-enriched fraction (Fig. 2B). We also found
that the levels of the ‘‘B’’ and ‘‘C’’ forms of Nrf3 are aug-
mented in the presence of MG-132 in both the cytosol and nu-
cleus.3.3. N-linked glycosylation state of hNrf3
Recent studies have shown that several leucine-zipper tran-
scription factors are targeted to ER including Nrf1 [19,20],
ATF6 (activating transcription factor 6) [21], OASIS (old
astrocyte speciﬁcally induced substance) [22], CREB4 (cAMP
response element-binding 4) [23], luman [24], CREBH (cAMP
response element-binding protein H) [25], Tisp40/AIbZIP
(transcript induced in spermiogenesis 40/androgen-induced
bZIP) [26], Bap31 (B-cell receptor-associated protein 31) [27]
and CREB3L2 (cAMP responsive element binding protein 3-
like 2) [28]. These proteins have been found to be glycosylated,
cleaved upon ER-stress and then translocated to the nuclei
where they function as transcription factors. This prompted
us to investigate the glycosylation state of Nrf3. We identiﬁed
seven potential sites for N-linked glycosylation in Nrf3
(Fig. 3). The location of those putative sites in Nrf3 sequence
is similar to the Asn/Ser/Thr-rich glycosylated domain recently
described in Nrf1 [20]. To examine the putative glycosylation
of Nrf3, lysates of transfected HEK293T cells and JAR cells
were incubated with PNGase F, an enzyme that removes all
types of N-linked glycosylation or with EndoH that removes
only high mannose but not complex forms. As shown in
Fig. 4A, addition of PNGase F or EndoH led to the disappear-
ance of the ‘‘A’’ form of Nrf3 demonstrating that this form, lo-
cated mainly in the ER, is glycosylated. The ‘‘B’’ and ‘‘C’’
forms are not modulated upon deglycosylation treatment
showing that these versions are unglycosylated. In addition,
we noticed that the ‘‘B’’ polypeptide is even increased with
PNGase F or EndoH treatments hypothesizing that this form
Fig. 3. Schematic representation of human Nrf3. The positions of the N-terminal homology box 1 (NHB1) domain, PEST sequence and putative
nuclear localization sequence (NLS) that are conserved across 3 species are indicated. Y indicates the potential N-linked glycosylation sites in Nrf3.
Amino acids in bold are identical to the consensus sequences. Underlined amino acids are also found in the NBH1 domain of Nrf1.
Fig. 4. The ER-associated form of human Nrf3 is glycosylated. (A) HEK293T cells were transfected with an expression construct coding for human
Nrf3 or with a control vector without insert (pMT2). Forty-eight hours post-transfection, total cell lysates were treated for 1 h with PNGase F or
with EndoH and then analyzed by immunoblot with puriﬁed Nrf3-speciﬁc antiserum and probed for actin as loading control (left panel). JAR cells
were serum-starved overnight and then treated or not for 6 h with 1 lMMG-132. Total cell lysates were prepared and treated for 1 h with PNGase F
or with EndoH and then were analyzed by immunoblot with puriﬁed Nrf3-speciﬁc antiserum (middle panel for PNGase F treatment and right panel
for EndoH treatment) and probed for actin as loading control. The lanes corresponding to the JAR cell extracts treated with MG-132 have been
exposed ﬁve times less than the lanes of untreated JAR cell extracts. (B) JAR cells were serum-starved overnight and then treated or not with 1 lg/ml
tunicamycin or 1 lM thapsigargin for 1, 2, 4 and 6 h. Whole cell extracts (30 lg) were analyzed with puriﬁed Nrf3-speciﬁc antiserum and probed for
actin as loading control.
5404 Z. Nouhi et al. / FEBS Letters 581 (2007) 5401–5406is the unglycosylated form of ‘‘A’’. Similar results are observed
for endogenous Nrf3 in JAR cells (Fig. 4A, middle and right
panels) and in MDA-MB-231 cells, a breast cancer cell line(data not shown). Finally, treatment of JAR cells with tunica-
mycin, an inhibitor of glycosylation, led to a decrease of the
‘‘A’’ form of Nrf3 4 h after treatment further supporting our
Z. Nouhi et al. / FEBS Letters 581 (2007) 5401–5406 5405data that only the ‘‘A’’ form is glycosylated (Fig. 4B). Similar
results were observed in MDA-MB-231 cells (data not shown).
We also observed lower protein levels of the ‘‘B’’ and ‘‘C’’
forms after 6 h of tunicamycin treatment when compared to
the untreated (DMSO) sample (Fig. 4B).3.4. Eﬀect of ER stress on hNrf3 expression level
Since Nrf3 is associated with the ER, we investigated the ef-
fect of thapsigargin, an agent promoting ER stress by deple-
tion of luminal calcium stores, on Nrf3 in JAR cells. As seen
in Fig. 4B, thapsigargin treatment led to lower levels of the
three Nrf3 forms after ER stress. Tunicamycin and thapsigar-
gin are both inducers of ER stress leading to the activation of
the Unfolded Protein Response [29]. Since our experiments
showed a modulation of the three Nrf3 forms upon ER stress,
it could be speculated that Nrf3 may act as an ER stress sensor
mediating the Unfolded Protein Response. However, further
experiments are required to conﬁrm this hypothesis.
We found that human endogenous Nrf3 is composed of
three forms: an ‘‘A’’ form which is glycosylated and located
in the endoplasmic reticulum and the unglycosylated ‘‘B’’
and ‘‘C’’ forms. Based on our preliminary data and recent
studies [19,20], we speculate that the ‘‘B’’ form is the full length
version of Nrf3 whereas the ‘‘C’’ form of Nrf3 might be trun-
cated. Indeed, it has been recently shown that N-terminal do-
main of Nrf1 consists of a signal peptide comprising the NHB1
motif that has previously been shown to be required to target
this CNC protein to the ER [20]. Zhang and collaborators
showed that deletion of this domain prevents retention of
Nrf1 in the ER which is then translocated to the nucleus. Bio-
informatics analysis of Nrf3 sequence revealed the presence of
a signal peptide in the N-terminal part of Nrf3. This signal
peptide also contains an NHB1-like sequence in its distal end
(Fig. 3). We thus hypothesize that this region may target
Nrf3 to the ER where it can be glycosylated. The ‘‘C’’ form
of Nrf3, found in the nucleus, may be a truncated form lacking
the NHB1 domain. Although, the process of translocation of
Nrf3 from the ER to the nucleus remains to be elucidated,
we hypothesize that Nrf3 might be cleaved by Site-1 protease
(S1P), a membrane-anchored serine protease located in the
lumen of the Golgi apparatus. Corroborating this hypothesis,
we found a putative S1P cleavage site in the NHB1 domain of
Nrf3 (Fig. 3). This cleavage site is not present in Nrf1. Of inter-
est, the well characterized transcription factors SREBP-1 (ste-
rol regulatory element binding protein-1), a major regulator of
cholesterol synthesis and ATF6, a basic-leucine zipper (bZIP)
transcription factor playing a role in the Unfolded Protein Re-
sponse are targeted to the ER [30,31]. Under certain condi-
tions, these ER-bound proteins are transported to Golgi and
then undergo two consecutive cleavages by Site-1 and Site-2
proteases (S2P). Following this intramembrane proteolysis,
SREBP-1 and ATF6 translocate into the nucleus where they
regulate the transcription of their target genes. Since we
showed that Nrf3 is associated with the ER and its sequence
comprises a putative S1P cleavage site, Nrf3 may be cleaved
in a manner similar to SREBP-1 and ATF6.
In conclusion, our data showed that Nrf3 is a stringently
regulated and posttranslationally modiﬁed transcription fac-
tor. We suggest that these modiﬁcations play a role in the con-
trol of Nrf3 activity in the cell. In addition, we showed that ER
stress conditions regulate the expression of Nrf3. Since Nrf3deﬁcient mice do not display an apparent phenotype under
normal conditions [13], it will be of interest to investigate the
response of these animals to ER stressors like thapsigargin
[32].
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